• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Glaukos Corporation Common Stock (NY:GKOS)

    172.46 +10.87 (+6.73%)
    Delayed Quote Updated: 11:24 AM EDT, Oct 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Glaukos Corporation Common Stock

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    News headline image
    Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View ↗
    Sight Sciences Inc (NASDAQ: SGHT) has treated the first patient in the TRIDENT trial evaluating OMNI Surgical System compared to Glaukos Corp's (NYSE... 
    Via Benzinga
    News headline image
    Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Glaukos: Q4 Earnings Insights ↗
    Glaukos (NYSE:GKOS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos... 
    Via Benzinga
    News headline image
    Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Earnings Scheduled For February 22, 2022 ↗
    Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
    Via Benzinga
    News headline image
    Analyst Ratings For Glaukos ↗
    Glaukos (NYSE:GKOS) has observed the following analyst ratings within the las... 
    Via Benzinga
    News headline image
    The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗
    Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
    Via Benzinga
    News headline image
    Glaukos Announces Executive Leadership Changes
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022 ↗
    Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
    Via Benzinga
    News headline image
    Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
    From Glaukos Corporation
    Via Business Wire
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022 ↗
    Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen... 
    Via Benzinga
    News headline image
    Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile ↗
    Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The... 
    Via Benzinga
    News headline image
    Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
    From Glaukos Corporation
    Via Business Wire
    News headline image
    The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name... 
    Via Benzinga
    News headline image
    A Peek Into The Markets: US Stock Futures Higher; All Eyes On Jobs Report ↗
    Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the key jobs data for December. Investors are awaiting earnings results from Acuity Brands,... 
    Via Benzinga
    News headline image
    5 Stocks To Watch For January 7, 2022 ↗
    Some of the stocks that may grab investor focus today are: Wall Street expects Acuity Brands, Inc. (NYSE: AYI) to report quarterly earnings at $2.41 per share on revenue of $... 
    Via Benzinga
    News headline image
    Glaukos Announces FDA 510(k) Clearance of iPRIME™
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Glaukos Corp (GKOS) FY 2021 Earnings Call Transcript ↗
    GKOS earnings call for the period ending November 29, 2021. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Glaukos Announces Participation in Upcoming Investor Conferences
    From Glaukos Corporation
    Via Business Wire
    News headline image
    FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure ↗
    The FDA has signed off Sight Sciences Inc's (NASDAQ: SGHT) clinical study to assess investigational higher volume OMNI device to perform canal viscodilation... 
    Via Benzinga
    News headline image
    Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting
    From Glaukos Corporation
    Via Business Wire
    News headline image
    Glaukos Corp (GKOS) Q3 2021 Earnings Call Transcript ↗
    GKOS earnings call for the period ending October 31, 2021. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Glaukos Corporation Announces Third Quarter 2021 Financial Results
    From Glaukos Corporation
    Via Business Wire
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.